CVNA Squeezing. ROOT and RXRX are Next

One month ago we mentioned the gamma squeeze coming up on Carvana (CVNA). Now that this is at hand and the stock has more than doubled, it's time to go long on two other heavily shorted stocks that stand to benefit from the CVNA squeeze as desperate shorts have to cover. These are Root, Inc. (ROOT) and Recursion Pharmaceuticals, Inc. (RXRX)


CVNA made a $126 million investment into ROOT and has embedded its insurance program into its systems. So any improvement in financial performance on CVNA implies that ROOT will also follow. It currently has 1.4 million in short interest, representing approximately 15% of the float. Not nearly as much as CVNA, but considering that ROOT trades only around 200,000 shares or so in a day, it can really take off in any sort of squeeze. Or as people realize that these two companies are financially linked and CVNA profits come heavily into ROOT. 

RXRX has doubled in price recently after a $50 million investment made by NVIDIA Corporation (NVDA). Shorts expected it to come down by now, except it hasn't, and is challenging new year highs. It has 18.5 million shares short, representing approximately 16% of the float. Recent shorts are now down over 100% and would be scrambling to cover on top of any short on CVNA. Historically, shorts on RXRX seem to be in at an average price of around $10. They were in profits but now they are staring down losses. 

Stocks like CVNA, ROOT and RXRX are all shorted by the same type of market players. If one position implodes on them, the rest follow. We see evidence of that as both ROOT and RXRX are up in pre-market as CVNA roars into the $50's. Expect ROOT and RXRX to really break out among some other heavily shorted stocks as shorts have to cover across the board to avoid margin calls and traders who won big on CVNA pour their profits into these similar types of stocks. 



Comments

Post a Comment

Popular posts from this blog

Carvana: The Gamma Squeeze is Real, Time to Bankrupt Kerrisdale

Image
Heavily shorted Carvana Co. (CVNA) is in the middle of a squeeze. One that looks eerily similar to the beginnings of the one we saw on GME that eventually made it run to $400 and took down Melvin Capital. Once again certain market players or commentators who focus on fundamentals and who misunderstand or downplay the short squeeze thesis will only add fuel to the fire as they short the stock. Will Carvana be able to refinance its debts next year? Will it become profitable by then? Who knows, and who cares. 2024 isn't the timeline here. The timeline starts as early as June 16, 2023. Triple witching day on options. This time Kerrisdale Capital is the target. The firm is in a desperate spot because the last short call it made was C3.ai, Inc. (AI). AI is in the middle of its own short squeeze and has nearly doubled into $40's since Kerrisdale tried taking it down: The AI report is still featured alongside on the CVNA one on Kerrisdale's website , so we can assume this position
Read more

The Next NVDA-Backed Runner and New Asian IPO Squeeze Play

Image
We have seen stocks like Super Micro Computer, Inc. (SMCI) and SoundHound AI, Inc. (SOUN) have incredible squeeze runs thanks to their connection to NVIDIA Corporation (NVDA). We think the next one will be Spire Global, Inc. (SPIR), which popped a week ago after it announced a collaboration with NVDA to enhance AI-driven weather prediction. A few day later it dropped on the announcement of a financing at $14, with the potential to raise $61 million if warrants at $14.50 are exercised. We think there is a good chance that NVDA got in on this financing, as it tends to invest in the companies it does these deals with when spreading AI across different sectors. One such recent example was with Recursion Pharmaceuticals, Inc. (RXRX) for AI in drug development.  It looks like SPIR didn't really need this financing as it has enough cash and looks like it will be cash flow and net income positive in 2024. This financing was of a strategic nature, not something led by brokers to fund a com
Read more

CVNA Squeezing, ROOT and RXRX are Next

Image
Earlier today we stated that Root, Inc. (ROOT) and Recursion Pharmaceuticals, Inc. (RXRX) were next to squeeze after Carvana (CVNA). One month ago  we mentioned  the gamma squeeze potential on CVNA. Now that this is at hand and the stock has more than doubled, it's time to go long on two other heavily shorted stocks that stand to benefit from the CVNA squeeze as desperate shorts have to cover.  The strategy worked perfectly as ROOT increased 19% and RXRX increased 16% on the day while CVNA rose another 40%. This will be just the beginning as shorts are hemorrhaging on multiple related positions. If you look at the chart for the day, it becomes very clear how highly correlated these three stocks are right now. This is undeniably a sign that shorts, particularly algo HFT shorts are covering simultaneously held positions.  CVNA  made a $126 million investment  into ROOT and has embedded its insurance program into its systems. So any improvement in financial performance on CVNA implie
Read more